A randomized study of docetaxel plus cisplatin verse paclitaxel plus cisplatin in untreated advanced non-small cell lung cancer

Objective To compare docetaxel plus cisplatin (DC) versus paclitaxel plus cisplatin (PC) for patients with advanced non -small cell lung cancer. Methods Eighty -two patients with advanced non -small cell lung cancer were randomly assigned to reive either DC or PC. Patients received docetaxel 75 mg,/m: on day 1 and cisplatin 75 mg/m2 divided into doses on days 2 to 4 in DC group and paclitaxel 150 mg/m2 on day 1 and cisplatin 75 mg/m2 divided into doses on days 2 to 4 in PC group.The cycle of two regimens was repeated every 3 weeks. Response and toxicity were evaluated in patients who completed two cycles of chemotherapy at least. Rusults There was no significant difference in response rate, median survival rate, median time to tumor progression or survival rate between two groups (P＞0.05 ) . There was no significant difference in grade Ⅲ and Ⅳ toxicities between two groups (P＞0.05). Conclusions Among the chemotherapy methods to advanced non - small cell lung cancer, DC has similar response rate and survivals with PC, and its toxicity is well - tolarated. Both of these methods are effective first- line treatment to non- small cell lung cancer. Key words: Chemotherapy; Docetaxel; Paclitaxel; Cisplatin